| dc.description.abstract | Fluoroquinolone is an important class of antibiotics that is used to treat infections caused by S. aureus. However, the increasing use of fluoroquinolones has led to increase in resistance of these antimicrobials, with rates of resistance that vary by both organism and geographic region. In previous studies, the numerous and complicated mutations observed may explain the rapid and widespread development of quinolone resistance described in S. aureus. The selected object for this study was demonstrated as a multidrug-resistant Staphylococcus aureus ATCC 29213 strain after FQs exposure. In this project, mgrA and recA have been characterized by using specific primers and sequencing of PCR products, as well as evaluating recA expression which was assessed by RT-PCR. The aim of this project is to check the presence and modification (if any) of mgrA and recA in fluoroquinolone- exposed S. aureus strains, either evaluating the expression of these genes in the strains. As a result, different amounts of RecA have been identified expression in exposure strains from the naïve one and, importantly, added a previously unknown coordinated and specific recA transcriptional response to antimicrobial exposures. These data provide evidences for the role of mgrA and recA in the S. aureus response to antimicrobials (FQs) and also opportunities for exploring new avenues for RecA-based therapies. Further study is conducted to find out repressors that inhibit RecA in order to suppress the development of antibiotic resistance, and investigate other antibiotic resistant mechanisms involve in the controlling expression of mgrA.
Keywords: Staphylococcus aureus, resistance, Fluoroquinolone, mgrA, recA | en_US |
